MarketPulse
A

$AARD

5 articles found
0 positive
4 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aardvark Therapeutics Stock Crashes 56% After Trial Pause; Fraud Investigation Launched

Aardvark Therapeutics stock plummeted 56.2% after halting Phase 3 trial due to cardiac observations. Law firm investigates potential securities fraud.
AARDsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Law Firm Launches Dual Investor Probes While Retracting Ambarella Notice

Pomerantz LLP investigates potential investor claims against Aardvark Therapeutics and FS KKR Capital Corp, while retracting prior Ambarella notice.
AARDFSKAMBAshareholder rightssecurities litigation
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Aardvark Therapeutics Stock Plummets 56% as Law Firm Probes Cardiac Safety Concerns

Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.
AARDsecurities fraudclass action lawsuit
BenzingaBenzinga··Rishabh Mishra

US Stock Futures Tumble as Iran Crisis Rattles Markets; Tech Stocks in Focus

U.S. stock futures fell on Iran tensions, while $HKD surged 20% on earnings and $AARD crashed 53% after trial pause.
SPYQQQALBTMDBAARD+2market volatilitystock market decline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aardvark Therapeutics Issues 152K Stock Options to New Hires

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.
AARDclinical-stagebiopharmaceutical